Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of INCB161734 in Advanced Solid Tumors With KRAS G12D Mutation
jRCT2031240694Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Apr 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 1, open-label trial of INCB161734 in Nonhematologic neoplasms (6 arms), sponsored by Incyte. Primary endpoints: Number of participants with Dose Limiting Toxicities (DLTs), Number of participants with Treatment-emergent Adverse Events (TEAEs) and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
INCB161734
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031240694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240694.